EXPLORER-HCM Trial finds substantial health status improvements with mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Share Article
Saint Luke s Mid America Heart Institute shared trial findings at American College of Cardiology’s 2021 Scientific Session
The benefits observed were amongst the largest we have ever seen from a medication to improve the symptoms, function and quality of life of patients with heart failure. KANSAS CITY, Mo. (PRWEB) May 20, 2021 The EXPLORER-HCM (Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) Randomized Clinical Trial has shown significant improvement in the symptoms, function, and quality of life in patients with obstructive hypertrophic cardiomyopathy (oHCM) with taking mavecamten. This comes following no major advances for treating oHCM in more than 30 years, where the primary goals of treat
Genentech, Myokardia veterans look to create new playbook against autoimmune diseases with $70M from Foresite Capital
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Former Genentech execs, including ex-CEO Ian Clark, jump in with IPO-seeking gene therapy company Gyroscope
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Former Genentech execs, including ex-CEO Ian Clark, jump in with IPO-seeking gene therapy company Gyroscope
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.